











 1.　2016年 5月 27日（金）行動医学分野担当
Lukas Van Oudenhove, MD, PhD : Translational 
Research Center for Gastrointestional Disorders （TAR-
GID）, KU Leuven, Belgium
“Neuroimaging of Brain-Gut Interactions”
要旨 : The importance of interactions between the brain and 
gastrointestinal tract has been recognized for decades.　It is 
now clear that this bidirectional communication occurs through 
a complex neurohumoral signaling system （the so-called 
‘brain-gut axis’） that not only regulates gastrointestinal 
homeostasis and digestion, but also integrates these periph-
eral processes with the overall physical and emotional state of 
the organism.　This is accomplished by integration of homeo-
static gut-brain signals with input from exteroceptive sensory 
systems, the reward system and affective & cognitive neuro-
circuits in the brain.　Under physiological circumstances, the 
majority of these homeostatic afferent signals is not con-
sciously perceived, with only salient or potentially noxious 
stimuli requiring a behavioral response reaching consciousness.　
However, dysfunction at any level of the brain-gut axis may 
result in aberrant perception of bodily signals, which may in 
turn lead to the generation of unexplained gastrointestinal 
symptoms such as visceral pain or dysregulation of food intake.　
Furthermore, recent （animal） evidence indicates an import 
impact of the gut microbiota on psychobiological processes 
through its influence on gut-brain signaling （‘microbiota-gut-
brain axis）, extending the potential relevance of gut-brain 
communication towards normal psychological functioning and 
neuropsychiatric disorders.　I will provide an overview of 
studies illustrating how functional neuroimaging has increased 
our understanding of the （microbiota）-gut-brain axis, and its 
crucial role in 1） functional gastrointestinal disorders, 2） food 
intake disorders, and 3） mood and anxiety disorders. 
（文責 : 鹿野理子）
 2.　2016年 7月 6日（水）災害医療国際協力学分野担当
Dr. Basu Dev Pandey : Ministry of Health, Govern-
ment of Nepal
“From Preparedness, Response to Recovery : 
Lived Experiences and Lesson learns of Nepal 
Earthquake 2015”
要旨 : ネパールで 2015年 4月 25日に発生したゴルカ地









































すが仙台防災枠組に謳われている Build Back Betterが達成
されることを心よりお祈り申し上げます．
（文責 : 江川新一）
 3.　2016年 7月 7日（木）耳鼻咽喉・頭頸部外科学分野
担当
Associate Professor Shinichi Someya, PhD : 
Department of Aging and Geriatric Research/University 
of Florida
“Sex Differences in Aging and Hearing Loss”
要旨 : Hearing loss is the third most prevalent chronic health 
condition, causes individuals to understand speech poorly, and 
affects the quality of life in older adults.　The most common 
type of permanent hearing loss is sensorineural hearing loss 
that results from damage to sensory hair cells or nerve fibers 
in the inner ear or auditory nerve.　Sensorineural hearing 
loss is caused by several contributing factors such as aging, 
genetic conditions, ototoxic chemicals, and noise exposure.　
Previous studies showed that hearing loss was less prevalent 
in females than males in virtually all age groups examined （20
～80 ≤ years of age） and that men lost hearing faster than 
women in the U.S. population between 2001 through 2008.　It 
is also well-established that women live longer than men in 
every country in the world.　Why do women live longer than 
men ?　Why do women hear better than men ?　This talk will 
review evidence that : 1） women live longer than men, that 2） 
female animals live longer than males, and that 3） women hear 
better than men.　I will also discuss our ongoing work aimed 
at testing hypotheses/questions about the mechanisms under-
lying sex differences in aging and hearing loss. 
（文責 : 染谷慎一）
 4.　2016年 7月 19日（火）発生発達神経科学分野担当
Prof. Carol Mason : Columbia University
“The path from eye to brain : Genes encoding neu-




























 5.　2016年 8月 1日（月）病理診断学分野担当
Dr. Viroj Boonyaratanakornkit : Faculty of Allied 
Health Sciences, Chulalongkorn University, Bangkok, 
Thailand
“Role Of Progesterone Receptor Extranuclear Sig-
naling In Breast And Lung Cancer”
要旨 : Our laboratory has long been interested in the role of 
progesterone receptor （PR） in endocrine-related cancer.　In 
breast cancer, we examined the apparent dichotomy that pro-
gesterone （P4） is proliferative in breast epithelium and a risk 
factor for breast cancer, yet PR expression in primary tumors 
is a favorable prognostic marker.　The proliferative effects of 
P4 are mediated by a combination of the nuclear actions of PR 
as a direct transcription factor and extra-nuclear actions of PR 
as a modulator of signal transduction pathways, including 
c-Src/MAPK and c-Src/PI3k/Akt pathways.　P4- dependent 
activation of these signaling pathways is mediated by direct 
PR-interaction with SH3 domain of c-Src.　We and others 
have observed that PR in breast cancer cells lines, in the 
absence of P4, has significant effects on gene expression.  By 
use of point mutations in the polyproline domain （PPD） of PR 
that interacts with SH3 domains （PR-BΔSH3）, we further 
identified that >300 gene change in the absence of P4 are 
dependent on PR interaction with SH3 domain targets and GO 
analysis indicated an enrichment of gene pathways involved in 
cell differentiation, polarity and motility.　Reintroduction of 
PR in the absence of P4 into PR null T47D cells resulted in 
suppression of EMT like characteristics including a change in 
cell shape, reduction in vimentin gene expression, reorganiza-
tion of cytoskeletal components, and reduction in cell motility.　 
These phenotypic changes were also dependent on PR inter-
action with SH3 domain targets since they were abrogated by 
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point mutations in the PR PPD.　Recently, we extended our 
investigation on the role of PR PPD in non-small cell lung can-
cer （NSCLC） since NSCLC with low PR expression was asso-
ciated with poor clinical outcomes.　We showed that expression 
of PRB but not PRBΔSH3 blocked EGF-induced A549 cell 
proliferation and EGF-induced activation of MAPK, in the 
absence of ligand.　Together, these data demonstrate the sig-
nificance of extra-nuclear signaling of PR through PPD inter-
actions and suggest that PR inhibition of breast cancer and 
NSCLC cell growth is mediated, in part, through its PPD.
（文責 : 笹野公伸）
 6.　2016年 9月 12日（月）内部障害学分野担当
劉　暁程 : 中国泰達国際心血管病病院　病院長・天
津医科大学教授
“Health service evolution in China and manage-





























 7.　2016年 9月 15日（木）腎・高血圧・内分泌科担当
Ms. Karen Lemaire, Ms. Christiane Fitzpatrick, Ms. 


































 8.　2016年 10月 3日（月）病態液性制御学分野担当
Shuei-Liong Lin, MD, PhD : Renal Division, National 
Taiwan University Hospital Graduate Institute of Physi-
ology, National Taiwan University College of Medicine
“Drug Discovery for Erythropoiesis in Chronic Kid-
ney Disease”
要旨 : Renal erythropoietin-producing cells remain in atro-
phic kidneys and are capable of producing erythropoietin in 
dialysis patients who take the stabilizer of hypoxia-inducible 
factors.　The mechanism of decreased response of renal 
erythropoietin-producing cells to anemic stimulation in 
chronic kidney disease remains unclear.　We use genetically 
modified mice who report pericytes/myofibroblasts or express 
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pericyte-specific Cre recombinase to perform in vivo study.　
We also isolate and purify pericytes/myofibroblasts from these 
mice for analysis of erythropoietin production and epigenetic 
modification.　Foxd1+ progenitor-derived ; Col1a1-GFP+ ; 
PDGFRβ+ kidney pericytes are erythropoietin-producing cells 
regulated by hypoxia-inducible factor 2α but decrease such a 
function upon their transition to myofibroblasts in fibrosing 
kidney disease and in vitro culture.　Hypermethylation of 
erythropoietin 5′-untranslated region is demonstrated and 
associated with decreased expression of erythropoietin in kid-
ney myofibroblasts.　Demethylation with 5-azacytidine or 
knockdown of upregulated DNA methyltransferase 1 in kidney 
myofibroblasts is found to increase expression of erythropoie-
tin in fibrosing kidney disease.　These studies demonstrate 
that epigenetic modifications may provide a molecular basis for 
decreased response of renal erythropoietin-producing cells to 
anemic stimulation in fibrosing kidney disease.
（文責 : 阿部高明）
 9.　2016年 10月 3日（月）病理診断学分野担当
Dr. Matthew J. Taylor : Molecular and Integrative 
Physiology University of Michigan
“Development of an inducible mouse model of pri-
mary aldosteronism”
要旨 : Introduction : Adrenal production of aldosterone is tig-
h tly controlled by the renin-angiotensin-aldosterone system.　
Aldosterone regulates renal sodium retention, thereby indi-
rectly impacting blood volume and pressure.　Furthermore, 
inappropriate adrenal aldosterone production is the hallmark of 
primary aldosteronism （PA）.　PA is an important cause of 
hypertension and it is estimated to affect 6-10% of the hyper-
tensive population.　Despite its prevalence, there are few in 
vivo animal models that accurately recapitulate the disease.　
Previous transgenic mouse models of PA have the disad-
vantage of being constitutive from birth, which is inconsistent 
with the typical onset of PA later in life.　This highlights a 
need for an inducible in vivo model of aldosterone excess.
Methods : Recently, a new in vivo transgenic technology, 
designer receptors exclusively activated by designer drugs 
（DREADD）, was invented to study G protein signaling path-
ways.　These transgenic modified G protein-coupled rec-
eptors can be regulated by treatment with an inert small 
molecule drug, clozapine n-oxide （CNO）, while lacking the 
ability to bind endogenous ligands.　Through Cre-targeted 
adrenocortical expression of Gq-DREADD, the aldosterone 
regulating Gq-signaling can be induced following CNO 
treatment.　Real-time RT-qPCR analysis of transcripts, 
immunofluorescence analysis of protein expression, and 
LC-MS/MS steroid analysis was used to assess the efficiency 
of DREADD-induced aldosterone production.
Results : Our preliminary data indicate that adrenal cortex-
targeted expression of Gq-DREADD, and its subsequent 
activation by chronic CNO treatment, significantly increased 
circulating aldosterone levels.　Compared to control animals, 
CNO treated mice had a robust increase in adrenocortical 
CYP11B2 （aldosterone synthase） transcript and protein 
levels, as well as plasma levels of 18-hydroxycorticosterone and 
aldosterone.
Conclusion : This inducible in vivo model will give insight 
to the molecular mechanisms involved in adrenal aldosterone 
production and provide an important tool for PA research.
（文責 : 笹野公伸）
10.　2016年 10月 17日（月）血液免疫病学分野担当
Dr. Tomas Ganz : University of California, Los Angeles
“Opposing effects of infection and hemorrhage on 






































Professor, Philippe Bouvet : Department of Molecular 
Biology and Biochemistry CNRS-Ecole Normale Super-
ieure de Lyon, France
“Nucleolin is a key protein required for the tran-




























RNAポリメラーゼ Iによる rRNAと RNAポリメラーゼ II
による mRNA転写を NCLが活性化することで統合的に調
節され，その結果 NCLは細胞分裂や増殖を制御すること
が考えられた．NCL自身の機能制御メカニズムの詳細は
明らかではないが，Prof. Bouvetはシグナル伝達による翻
訳後修飾に注目した研究も進めている．例えば，88番目
のリジンがアセチル化された NCLは核小体から解離し，
スプライシングファクター SC35と結合することで mRNA
成熟に関与する．NCLタンパク質アミノ酸には CKIIや
ERKによるリン酸化部位が数多く同定されており，これ
らのリン酸化酵素による NCL機能制御の詳細な解析が待
たれる．さらに，NCLは急性骨髄性白血病（AML）患者
の腫瘍細胞で増加しており高 NCL発現は予後と関連する
ことから，臨床における新規の診断マーカーとしての活用
も期待される．
（文責 : 落合恭子）
